Health Care Resource Utilization and Costs of Persistent Severe Acute Kidney Injury (PS-AKI) Among Hospitalized Stage 2/3 AKI Patients
Kidney360 · 2023-03 · 4 (3) · 316-325
DOI: 10.34067/kid.0005552022 ↗Kurz gefasst
Fachartikel in der Zeitschrift Kidney360, 2023-03. Verfasst von Jay L Koyner und 10 weiteren Autor:innen. Beteiligte Einrichtung: Section of Nephrology, University of Chicago, Chicago, Illinois. Hauptthemen laut MEDLINE: Acute Kidney Injury. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: bioMerieux, Inc..
Abstract (Originalsprache)
Key Points Among hospitalized patients with stage 2/3 AKI, persistent severe acute kidney injury (PS-AKI) is associated with significantly longer length of stay (LOS) and higher costs during index hospitalization and 30 days postdischarge. Relative differences in LOS and costs for PS-AKI versus NPS-AKI were similar for intensive care (ICU) and non-ICU patients. Preventing PS-AKI among patients with stage 2/3 AKI may reduce hospital LOS and costs.
Background
Persistent severe acute kidney injury (PS-AKI) is associated with worse clinical outcomes, but there are no data on costs of PS-AKI. We compared costs and health care resource utilization for inpatients with PS-AKI versus not persistent severe AKI (NPS-AKI) overall and by ICU use.
Methods
This retrospective observational study included 126,528 adult US inpatients in the PINC AI Healthcare Database (PHD), discharged from January 1, 2017, to December 31, 2019, with KDIGO stage 2 or 3 AKI (by serum creatinine [SCr] criteria) during hospitalization, length of stay (LOS) ≥3 days, and ≥3 SCr measurements. Patients were categorized as PS-AKI (defined as stage 3 AKI lasting ≥3 days or with death within 3 days or stage 2/3 AKI (by SCr criteria) with dialysis within 3 days) or NPS-AKI. Generalized linear model regression compared LOS and costs during index hospitalization (total cohort) and 30 days postdischarge (survivors of index hospitalization), adjusted for patient, hospital, and clinical characteristics.
Results
Among 126,528 patients with stage 2/3 AKI, 30,916 developed PS-AKI. In adjusted models, compared with NPS-AKI, patients with PS-AKI had 32% longer total LOS (+3.3 days), 45% longer ICU LOS (+2.6 days), 46% higher total costs (+$13,143), 58% higher ICU costs (+$15,908), and during 30 days postdischarge 13% longer readmission LOS (+1.0 day), 22% higher readmission costs (+$4049), and 12% higher outpatient costs (+$206) ( P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Section of Nephrology, University of Chicago, Chicago, Illinois.
- Premier, Inc., PINC AI Applied Sciences, Charlotte, North Carolina, USA.
- Department of Epidemiology, University of Pittsburgh School of Public Health, Pittsburgh, Pennsylvania.
- Astute Medical Inc. (a bioMerieux company), San Diego, California.
- Baxter Healthcare, Global Medical Affairs, Deerfield, Illinois.
- bioMerieux, Inc., Global Medical Affairs, Durham, North Carolina.
Förderung
- bioMerieux, Inc.
Zitieren
APA
Koyner, J. L., Mackey, R. H., Rosenthal, N. A., Carabuena, L. A., Kampf, J. P., Echeverri, J., McPherson, P., Blackowicz, M. J., Rodriguez, T., Sanghani, A. R., & Textoris, J. (2023). Health Care Resource Utilization and Costs of Persistent Severe Acute Kidney Injury (PS-AKI) Among Hospitalized Stage 2/3 AKI Patients. Kidney360, 4(3), 316-325. https://doi.org/10.34067/kid.0005552022
Vancouver
Koyner JL, Mackey RH, Rosenthal NA, Carabuena LA, Kampf JP, Echeverri J, et al. Health Care Resource Utilization and Costs of Persistent Severe Acute Kidney Injury (PS-AKI) Among Hospitalized Stage 2/3 AKI Patients. Kidney360. 2023;4(3):316-325. doi:10.34067/kid.0005552022
BibTeX
@article{Koyner2023,
author = {Koyner, Jay L and Mackey, Rachel H and Rosenthal, Ning A and Carabuena, Leslie A and Kampf, J Patrick and Echeverri, Jorge and McPherson, Paul and Blackowicz, Michael J and Rodriguez, Toni and Sanghani, Aarti R and Textoris, Julien},
title = {Health Care Resource Utilization and Costs of Persistent Severe Acute Kidney Injury (PS-AKI) Among Hospitalized Stage 2/3 AKI Patients},
journal = {Kidney360},
year = {2023},
volume = {4},
number = {3},
pages = {316--325},
doi = {10.34067/kid.0005552022}
}
EUVIMED